193 results
Page 9 of 10
8-K
EX-99.1
b0n2quk ddi3g0
29 Apr 19
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
9nud yggcl
23 Apr 19
Moleculin Announces $15.0 Million Registered Direct Offering
9:34pm
8-K
EX-1.1
gg3qr9ev3gudr18nf
23 Apr 19
Moleculin Announces $15.0 Million Registered Direct Offering
9:34pm
PRER14A
i6r1hxltdrzir0ca3db
12 Apr 19
Preliminary revised proxy
4:03pm
8-K
EX-99.1
9z9esk
11 Apr 19
Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial
4:11pm
8-K
EX-99.2
okbgekrik 2mbzo
28 Mar 19
Moleculin Announces Proposed Underwritten Public Offering
6:18am
8-K
EX-1.1
jp5o7dbh
28 Mar 19
Moleculin Announces Proposed Underwritten Public Offering
6:18am
8-K
EX-99.1
jkvf0h dbl
28 Mar 19
Moleculin Announces Proposed Underwritten Public Offering
6:18am
8-K
EX-99.1
mxuja
26 Mar 19
Moleculin Announces Positive Interim Results in First Cohort of
7:31am
8-K
EX-99.1
hqn6pao8c6kbz8ws
14 Mar 19
Moleculin Announces First Patients Treated in European Annamycin Clinical Trial
4:20pm
8-K
EX-99.1
r34wi9bx9dokmrwi8j
21 Feb 19
Results of Operations and Financial Condition
4:32pm
8-K
EX-99.1
azu 4qytt4
7 Feb 19
Moleculin Announces Approval for Third Drug to Commence Clinical Trials
4:01pm
8-K
EX-99.1
pvtbt42o62
5 Feb 19
Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug
4:26pm
8-K
EX-99.1
ie1g1c1gv296n
12 Dec 18
Regulation FD Disclosure
5:28pm
8-K
EX-99.1
u0mcmtwq
13 Nov 18
Results of Operations and Financial Condition
7:31am
8-K
EX-10.1
6b5rk0u145
5 Oct 18
Entry into a Material Definitive Agreement
5:00pm